Antisense insulin-like growth factor binding protein...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C536S024500

Reexamination Certificate

active

10380195

ABSTRACT:
Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.

REFERENCES:
patent: 5929040 (1999-07-01), Werther et al.
patent: 6284741 (2001-09-01), Werther et al.
patent: WO 00/69454 (2000-11-01), None
Steller, et al. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. Proc. Natl. Acad. Sci., Dec. 1995, vol. 92, pp. 11970-11974.
Corkins et al. Growth Stimulation By Transfection of Intestinal Epithelial Cells With An Antisense Insulin-Like Growth Factor Binding Protein-2 Construct. Biochem. Biophys. Res. Com. Jun. 26, 1995, vol. 211, No. 3, pp. 707-713.
Wang, et al. Correlation of Glioma Cell Regression with Inhibition of Insulin-Like Growth Factor Binding Protein-2 Expression. Neuroendocrinology. 1997, vol. 66, pp. 203-211.
Bubendorf, et al., “Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays”, Oct. 20, 1999, pp. 1758-1764, vol. 91, No. 20, Publisher: Journal of the National Cancer Institute; US Dept. of Health, Education and Welfare; Public Health, Published in: USA.
Forsyth, et al., “Growth Inhibition of a Human Colon Cancer Cell Line by Antisense Oligonucleotide to IGFBP-2”, 1995, p. A726, vol. 108, No. 4, Publisher: Gastroenterology, Saunders, Published in: Philadelphia, PA, USA.
Gleave, et al., “Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer”, 2003, pp. 209-221, vol. 4, No. 3, Publisher: Current Drug Targets; Bentham Science Publisher, Published in: USA.
Miyake, et al., “Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models”; Jun. 1, 2000, pp. 3058-3064, Publisher: Cancer Research, American Association for Cancer Research, Published in: Baltimore, MD, USA.
Binkert, et al., “Structure of the Human Insulin-Like Growth Factor Binding Protein-2 Gene”, 1992, pp. 826-836, vol. 6, No. 5, Publisher: Molecular Endocrinology, Published in: US.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antisense insulin-like growth factor binding protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense insulin-like growth factor binding protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense insulin-like growth factor binding protein... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3765092

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.